The managing partners: the Trust, MDC & (since September 2022) LifeArc, work together with pwCF, academics, industry & clinical collaborators globally to deliver the goals of the Syndicate.

Cystic Fibrosis (CF) and Antimicrobial Resistance (AMR)
Creation of the CF AMR Syndicate

AMR is a leading cause of death globally. Antibiotics remain a crucial therapeutic for people with cystic fibrosis (pwCF) as recurrent and increasingly multidrug resistant respiratory infections dominate as a cause of morbidity and mortality. While highly effective modulator therapy has had a positive effect on infection, their long term effects are unknown and infections have not been eradicated. There also remains a population of pwCF who are unable to benefit from modulator therapy. There is, therefore, an urgent and unmet need for the development of new antimicrobials to treat respiratory infections in CF.

The managing partners; the Trust, MDC & (since September 2022) LifeArc, work together with pwCF, academics, industry & clinical collaborators globally to deliver the goals of the Syndicate.

The CF AMR Syndicate

Our Goals:
- Build supporting tools and resources for translation of CF antimicrobial therapies and diagnostic development
- Create a unique cross-sector CF AMR Network to facilitate collaboration and knowledge exchange
- Identify, enable and support CF antimicrobial and diagnostic programmes

Our Mission:
- Accelerate the translation and adoption of new CF antimicrobials and diagnostics to the clinic, through collaboration. Bring new treatments to people with CF, faster.

The CF AMR Syndicate

The Syndicate is rapidly establishing itself as a unique entity facilitating the acceleration of novel antimicrobial and diagnostic discovery, helping inform those working in the drug and diagnostic discovery space.

#CFAMRSyndicate #AMR #medicinesdiscovery #collaboration #entrepreneurship

Support and Grow the CF Antimicrobial Pipeline

We work with innovators bringing Syndicate-developed resources, expertise and wider network to impact on their programmes. We will launch a new funding call for novel antimicrobials in the discovery phases in early 2023.

Funded by: LifeArc

Funded by: CF AMR Syndicate

CF AMR Network

Catalysing Innovation

We work with innovators bringing Syndicate-developed resources, expertise and wider network to impact on their programmes. We will launch a new funding call for novel antimicrobials in the discovery phases in early 2023.

The CF AMR Syndicate

Funding provided by LifeArc

Patient-focused Target Product Profiles

The TPPs provide guidance for drug & infection diagnostic developers on the key characteristics and requirements necessary to successfully address the needs and priorities of pwCF.

Antimicrobial therapeutic TPPs

(Available via our website)

A suite of TPPs to guide developers in the requirements of antimicrobials targeting P.aeruginosa, other gram negative pathogens and NTM.

Diagnostic TPPs

(Under development)

A suite of TPPs to guide developers in the requirements of diagnostic tests for improved management and treatment of lung infections are under development.

PF-LOSE

Funded by: LifeArc

Funded by: CF AMR Syndicate

The CF AMR Syndicate Website

Blog / News / Resources

Events, Workshops & Focus Groups

Knowledge exchange & problem solving

Networking & Signposting

Catalysing collaborations

Towards a Toolkit of Enabling Resources

The UK CF Infection Biorepository

A coordinated national network of labs which enables researchers from academia and industry to access well characterised, high quality clinically relevant samples, data and expertise.

UK CF Infection Biorepository

Funded by: LifeArc

Funded by: CF AMR Syndicate

Conclusions

Through the Syndicate, insights into the needs and priorities of pwCF are made visible, critically informing those working in the drug and diagnostic discovery space.

Acknowledgements

The CF AMR Syndicate Steering Committee and all members of the wider community that have supported us with this initiative.

To work with us and/or join our CF AMR Network please find us at www.cfamr.org.uk

www.cfamr.org.uk

References


CF AMR Syndicate

Managing Partners: Medicines Discovery Catapult Alderley Park, Cheshire, SK10 4ZF, UK
Cystic Fibrosis Trust Orme Adapts, London, E2N 3J, UK
LifeArc Lynton House, 7-12 Tavistock Square, London, WC1H 9LT, UK

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate

CF AMR Syndicate